Canlyniadau Chwilio - Max Sauter

  • Dangos 1 - 6 canlyniadau o 6
Mireinio'r Canlyniadau
  1. 1
    Radiolabeling Strategies for Tumor-Targeting Proteinaceous Drugs

    Radiolabeling Strategies for Tumor-Targeting Proteinaceous Drugs gan Grant Sugiura, Helen Kühn, Max Sauter, Uwe Haberkorn, Walter Mier

    Cyhoeddwyd 2014
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  2. 2
    Effect of Staggered vs. Simultaneous Co-Administration of Bempedoic Acid on Pharmacokinetics of Pravastatin: Randomized, Cross-Over Clinical Trial in Healthy Volunteers

    Effect of Staggered vs. Simultaneous Co-Administration of Bempedoic Acid on Pharmacokinetics of Pravastatin: Randomized, Cross-Over Clinical Trial in Healthy Volunteers gan Felicitas Stoll, Salvatore Amato, Max Sauter, Jürgen Burhenne, Johanna Weiß, Walter E. Haefeli, Antje Blank

    Cyhoeddwyd 2025
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  3. 3
    Identification of a Novel ITGαvβ6-Binding Peptide Using Protein Separation and Phage Display

    Identification of a Novel ITGαvβ6-Binding Peptide Using Protein Separation and Phage Display gan Annette Altmann, Max Sauter, Saskia Roesch, Walter Mier, Rolf Warta, Jürgen Debus, Gerhard Dyckhoff, Christel Herold‐Mende, Uwe Haberkorn

    Cyhoeddwyd 2017
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  4. 4
    Comparison of the RGD Motif–Containing α<sub>v</sub>β<sub>6</sub> Integrin–Binding Peptides SFLAP3 and SFITGv6 for Diagnostic Application in HNSCC

    Comparison of the RGD Motif–Containing α<sub>v</sub>β<sub>6</sub> Integrin–Binding Peptides SFLAP3 and SFITGv6 for Diagnostic Application in HNSCC gan Saskia Roesch, Thomas Lindner, Max Sauter, Anastasia Loktev, Paul Flechsig, Martin Müller, Walter Mier, Rolf Warta, Gerhard Dyckhoff, Christel Herold‐Mende, Uwe Haberkorn, Annette Altmann

    Cyhoeddwyd 2018
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  5. 5
    Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC

    Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC gan Xu Zhou, Jingyu An, Roma Kurilov, Benedikt Brors, Kai Hu, Teresa Peccerella, Stephanie Roessler, Katrin Pfütze, Angela Schulz, Stephan Wolf, Nicolas Hohmann, Dirk Theile, Max Sauter, Jürgen Burhenne, Shigenori Ei, Ulrike Heger, Oliver Strobel, Simon T. Barry, Christoph Springfeld, Christine Tjaden, Frank Bergmann, Markus W. Büchler, Thilo Hackert, Franco Fortunato, John P. Neoptolemos, Peter J. Bailey

    Cyhoeddwyd 2023
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  6. 6
    The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models

    The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models gan Romain Sigaud, Lisa Rösch, Charlotte Gatzweiler, Julia Benzel, Laura von Soosten, Heike Peterziel, Florian Selt, Sara Najafi, Simay Ayhan, Xenia F. Gerloff, Nina Hofmann, Isabel Büdenbender, Lukas Theo Schmitt, Kathrin I. Foerster, Jürgen Burhenne, Walter E. Haefeli, Andrey Korshunov, Felix Sahm, Cornelis M. van Tilburg, David Jones, Stefan M. Pfister, Deborah Knoerzer, Brent Kreider, Max Sauter, Kristian W. Pajtler, Marc Zuckermann, Ina Oehme, Olaf Witt, Till Milde

    Cyhoeddwyd 2022
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:

Offerynnau Chwilio: